Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin.

. The review is de­voted to the most important aspects of primary mixed dyslipidemia treatment in patients at high risk with concomitant metabolic comorbidities. Evidences for novel modern approaches regarding primary prevention of cardiovascular events among dyslipidemic patients are considered. The potential role of lipid-lowering treatment with statins and their role in reducing the cardiovascular risk are discussed. Information about modern methods of minimization of residual cardiovascular risk using a combined lipid-lowering strategies and new representatives of the statins are provided.Ithasbeendiscussedvariousstrategiesofstatinadministeringtopatientswithdyslipidemiaof different agewith exiting comorbidities, such as diabetes mellitus, obesity, metabolic syndrome. Objective findingsand treatment approaches obtainedfromthe patientwithobesity, metabolic syndrome, and asymptomatic atherosclerosis are provided. The role of pitavastatin in primary prevention program of cardiovascular events is discussed.